HMB Supplementation Research: What It Does

HMB sits in an unusual spot on the supplement shelf. It is one of the few nutritional compounds the International Society of Sports Nutrition has issued a formal position stand on, twice, once in 2013 and again in 2024. It has a solid mechanistic story rooted in leucine metabolism and muscle protein turnover. And yet if you handed the entire HMB literature to a young resistance-trained lifter reading it fresh, the honest takeaway would be: "this does not do very much for me." Handed to a 72-year-old with sarcopenia recovering from a hospital stay, the same literature reads very differently.

The gap between those two audiences is the whole story with HMB. It is not a case of good evidence versus bad evidence. It is a case of a compound that lands almost exactly where the marketing does not want it to land: in older adults with muscle wasting, in patients coming off bed rest, in the clinical-nutrition aisle. It is marketed to and priced for the sports-supplement aisle, where the best-designed meta-analysis in healthy young lifters says it does not meaningfully move fat-free mass or 1-rep max.

This article walks through what the last three decades of research actually show, in whom, at what dose, and for how long, and separates the settings where HMB is a real tool from the settings where it is not.

The Research: What Studies Show

Nissen 1996: The Founding Trial

The HMB story starts with Nissen, Sharp, Ray and colleagues (1996), publishing in the Journal of Applied Physiology. This was the first human trial to test whether the leucine metabolite HMB, added on top of a resistance training program, would improve gains in lean body mass and strength. The paper's positive findings launched the entire commercial category.

The design was two experiments in one. In the first, untrained men were randomized to placebo, 1.5 g/day HMB, or 3 g/day HMB alongside three-times-weekly resistance training for three weeks. Both plasma markers of muscle damage and gains in total weight lifted improved in a dose-dependent pattern, and lean body mass gains tracked the same curve (roughly 0.4, 0.8, and 1.2 kg for placebo, 1.5 g, and 3 g respectively). In the second, participants trained daily over seven weeks on either placebo or 3 g/day HMB and again saw superior gains in the HMB arm. Both experiments together framed the initial hypothesis: HMB slows exercise-induced muscle protein breakdown enough to shift the net protein balance and, over weeks, enough to show up as additional lean tissue and strength.

That founding trial did what founding trials often do. It carried the field for a decade largely on its own, and the replication picture that followed turned out to be much messier.

Wilson 2013: The First ISSN Position Stand

Almost twenty years in, Wilson, Fitschen, Campbell and colleagues (2013) published the first International Society of Sports Nutrition position stand on HMB in the Journal of the International Society of Sports Nutrition. Position stands are field consensus documents. They carry more weight than any single trial because they weigh the totality of the evidence, weigh study quality, and are written to guide practice.

The 2013 position stand landed on a set of practical conclusions that largely still hold. HMB, given at roughly 3 g per day, split into three servings, taken for at least two weeks before an anticipated hard training block, appeared to attenuate exercise-induced skeletal muscle damage and improve markers of recovery. The clearest signal was in populations undergoing a novel or intensified training stimulus, and in older adults. The paper was less enthusiastic about young, well-trained lifters already deep into a well-designed program, where the marginal effect looked small.

Deutz 2013: The Bed-Rest Trial

The single cleanest applied result in the entire HMB literature is Deutz, Pereira, Hays and colleagues (2013), published in Clinical Nutrition. This was a randomized, controlled, double-blind trial in 24 healthy older adults (mean age around 67, 20 women and 4 men), all confined to complete bed rest for ten days followed by eight weeks of resistance training rehabilitation. Subjects received either 3 g per day of calcium HMB (1.5 g twice daily) or a matched placebo powder throughout.

The result was striking. Ten days of complete bed rest costs older adults a measurable amount of lean tissue. Healthy older adults typically lose around 6 percent of their lower-extremity muscle in that window, and that loss is a leading contributor to why a hospital stay in later life is such a functional turning point. In the Deutz trial, the placebo group lost lean body mass over the 10-day bed rest as expected. The HMB group did not. Muscle mass was preserved during disuse. The paper's stated conclusion was measured (results needed to be confirmed in a larger trial) but the effect size on the primary outcome was large enough to shape almost every subsequent clinical HMB paper.

This is the trial that most cleanly justifies HMB's place in the clinical-nutrition toolkit. It is also the trial almost never featured in the sports-supplement marketing, because the reader profile is a hospitalized 67-year-old, not a 25-year-old lifting for hypertrophy.

Jakubowski 2020: The Young Lifter Meta-Analysis

The single most important paper for understanding what HMB does not do is Jakubowski, Nunes, Teixeira and colleagues (2020), publishing in Nutrients. Their team synthesized the young-adult resistance-training literature under strict inclusion criteria: double-blind, randomized, placebo-controlled trials only, with participants aged 18-45. Eleven trials met the bar, covering 302 participants for body composition analysis and 248 for strength.

The results were, statistically, a null. Fat-free mass showed a small nonsignificant advantage for HMB (mean difference 0.29 kg, p=0.06). Fat mass showed essentially nothing (0.10 kg, p=0.57). And on 1-rep-max strength, whether measured on the bench press, on lower-body compound lifts, or as a total, HMB produced no significant improvement over placebo. The authors' stated conclusion was blunt for a peer-reviewed meta-analysis: "HMB is not an effective anabolic supplement" for young resistance-trained adults.

Two things about this paper matter. First, it excluded studies with clear methodological problems, which had a lot to do with why previous, more permissive reviews looked more favorable. Second, it aligns with the general pattern across supplement science: compounds that show large effects in the first small trials tend to shrink toward zero as the field runs larger, better-controlled work. HMB in young resistance-trained adults is a textbook example.

Su 2024 and Li 2025: The Sarcopenia Meta-Analyses

The story in older adults is much more encouraging. Two recent meta-analyses set the current picture.

Su, Zhou, Gong and colleagues (2024), publishing in Frontiers in Medicine, pooled six RCTs in patients diagnosed with sarcopenia by consensus clinical criteria (667 patients on the primary handgrip outcome). HMB or HMB-rich nutritional supplementation produced a mean handgrip strength gain of 1.26 kg (95% CI 0.41 to 2.21, p=0.004). The stratified analysis was informative: the significant handgrip benefit showed up specifically in trials of 12 weeks or longer, not in shorter interventions. Gait speed, fat-free mass, fat mass, and skeletal muscle index changes did not reach statistical significance in this pooled analysis. HMB, at least at the doses studied, moved strength more clearly than it moved raw muscle mass in this population.

Li, Chen, He and colleagues (2025), publishing in Frontiers in Nutrition, went broader. They pooled 21 RCTs and 1,935 participants over age 50 (967 intervention, 968 control) and reported gains across every outcome examined: appendicular skeletal muscle mass +1.56 kg (95% CI 0.03 to 3.09), whole-body lean mass +0.28 kg (0.16 to 0.41), handgrip +0.54 kg (0.04 to 1.04), five-time chair stand -0.73 seconds (-1.35 to -0.11), and gait speed +0.05 m/s (0.01 to 0.09). Their subgroup analysis converged on a specific practical protocol: 3 g per day for longer than 12 weeks produced the clearest effect. Doses below 3 g per day were weaker. Intervention shorter than 12 weeks was weaker.

Rathmacher 2024: The Updated ISSN Position Stand

The current consensus document is Rathmacher, Pitchford, Stout and colleagues (2024), the updated International Society of Sports Nutrition position stand on HMB in the Journal of the International Society of Sports Nutrition. The authors drew on a database of more than 750 original articles and reviews accumulated since the 2013 version and reached a set of conclusions that are both more careful and more honest about who HMB helps.

The dose recommendation is approximately 38 mg per kilogram of body weight per day, which for most adults comes out to 3 g per day. The position stand endorses HMB use in three settings: alongside resistance training in older adults (to improve muscle strength and function), during periods of muscle disuse or clinical wasting (to attenuate the loss of lean tissue), and in some athlete populations undergoing novel or intensified training (to blunt exercise-induced muscle damage and support recovery). Two commercially available forms are covered: calcium HMB (HMB-Ca), typically taken as three 1 g doses spread across the day, and the free-acid form (HMB-FA), typically 1 g taken 30 to 60 minutes pre-workout. HMB-FA reaches peak plasma concentrations faster than HMB-Ca, but head-to-head training-outcome comparisons remain thin.

Notably, the 2024 position stand is more measured about HMB in healthy young resistance-trained adults than the 2013 version was. It acknowledges the Jakubowski 2020 meta-analysis directly and frames the training-status question the way the meta-analytic data supports it: benefits are most pronounced in untrained individuals and in older adults; effects in well-trained athletes are variable and only appear at meaningful magnitude after longer intervention durations (typically past six weeks).

How HMB Actually Works

HMB is a downstream metabolite of the branched-chain amino acid leucine. When you eat protein, some of the leucine gets converted through a two-step enzymatic pathway to alpha-ketoisocaproate (KIC) and then to HMB. The catch is that only about 5 percent of dietary leucine takes this route. The rest gets used for direct protein synthesis, oxidized for energy, or funneled into other metabolic pathways. So even a large protein meal delivers relatively little HMB. To reach the 3 g per day dose used in the training literature from food alone, you would need roughly 60 g of leucine per day, which corresponds to something like 500 to 600 g of protein. That is why the oral supplement matters. It delivers a dose the food supply cannot.

Once absorbed, HMB appears to act primarily on the muscle protein breakdown side of the equation, not the synthesis side. The molecular story runs through the ubiquitin-proteasome pathway, the primary route the body uses to tag and dismantle damaged or unnecessary muscle proteins. HMB downregulates that pathway. It also appears to support membrane stability in muscle cells (possibly through a cholesterol-precursor role) and to modulate mitochondrial dynamics in ways that plausibly matter during disuse.

That mechanism explains the audience mismatch. In a healthy young trained adult eating adequate protein and lifting hard, muscle protein breakdown is not the rate limiter. Muscle protein synthesis is, and the levers that move synthesis meaningfully in that population are protein intake, training stimulus, and creatine, not HMB. In an older adult with elevated basal proteolysis, sarcopenia, or acute disuse, breakdown is a much bigger part of the problem, and a compound that specifically brakes breakdown lines up with the mechanism.

Why This Matters for Your Fitness

Reading the HMB literature as a healthy adult in your 20s, 30s, or 40s who lifts regularly and eats enough protein, the honest answer is that HMB is probably not the supplement that will move your training. The Jakubowski meta-analysis is not the only signal in this direction. Almost every well-controlled young-adult trial with adequate baseline protein has produced modest or null results. If you are choosing one evidence-backed supplement to add, choose creatine monohydrate. The evidence base is dramatically stronger, the effect on strength and lean mass is meaningfully larger, and it costs less.

Reading the same literature as an adult over 60, especially one already experiencing signs of sarcopenia (lower handgrip strength, slower gait, difficulty rising from a chair), or as a caregiver for someone in that situation, HMB looks quite different. The Li 2025 meta-analysis is one of the largest pooled analyses in the aging-and-supplement space, and the direction is consistent across muscle mass, handgrip, chair-stand time, and gait speed. That is a rare cluster of aligned outcomes in a supplement literature that usually shows one thing at a time. Combined with the Deutz bed-rest trial, HMB has a real, replicated place in the clinical-nutrition toolkit.

The third reader is someone anticipating a planned disuse period: an upcoming knee or hip replacement, a scheduled prolonged hospital stay, an injury requiring immobilization. This is the group with arguably the strongest single-trial case. Ten days of bed rest costs older adults measurable lean tissue and can be a functional inflection point. If your care team is open to it, 3 g per day of calcium HMB during the immobilization window, split into two 1.5 g servings, is a low-risk, evidence-backed intervention with published trial support.

Where HMB does not fit: as a substitute for adequate protein intake (roughly 1.6 g per kg per day for training-age adults, 1.2 to 1.6 g per kg for older adults spread across meals), as a substitute for a resistance training program, or as a fat-loss aid. Nothing in the meta-analytic literature supports HMB as a fat-loss tool independent of training.

How to Use HMB in Practice

Translating the evidence into a workable protocol:

• Target 3 g per day. That is the dose in the 2024 ISSN position stand and the sarcopenia meta-analyses. Doses below 3 g per day underperform in the Li 2025 subgroup analysis. Doses above 3 g per day have not shown proportionately larger effects.
• Choose the form that fits your day. Calcium HMB (HMB-Ca) is typically split into three 1 g servings across the day. Free-acid HMB (HMB-FA) is typically 1 g taken 30 to 60 minutes before a workout. HMB-FA reaches peak plasma concentrations faster, but head-to-head training-outcome comparisons have not shown one form is clearly superior. If cost matters, HMB-Ca is usually less expensive.
• Give it at least 12 weeks. The sarcopenia meta-analyses converge on the same finding: benefits on handgrip, muscle mass, and gait speed show up specifically in trials running longer than 12 weeks at 3 g per day. Shorter interventions are underpowered to detect the effect. Do not judge HMB on a month.
• Take it alongside resistance training. The 2024 position stand is explicit that the benefits in older adults show up when HMB is combined with a resistance program, not when HMB is taken as a standalone. This matches the mechanism. HMB brakes breakdown; the training provides the synthesis stimulus.
• Consider it around planned disuse. If you are scheduled for surgery, immobilization, or prolonged bed rest, the Deutz 2013 evidence supports 3 g per day of calcium HMB during the disuse window as a muscle-preservation aid, especially in older adults. Talk to your care team about whether it fits your regimen.
• Do not use it as a replacement for protein. HMB is a metabolite. It does not deliver amino acids for protein synthesis. Total daily protein still matters (roughly 1.6 g per kg per day for training adults, 1.2 to 1.6 g per kg for older adults) and no amount of HMB compensates for underhitting that.
• If you are a healthy young resistance-trained adult with adequate protein, skip it. The Jakubowski 2020 meta-analysis is unambiguous on this reader profile. Spend the supplement budget on creatine monohydrate (3 to 5 g per day) instead.
• Do not stack HMB with high-dose leucine expecting synergy. The leucine-to-HMB conversion is capped by enzyme rate, not by substrate availability. Taking large doses of leucine on top of HMB does not raise HMB further and duplicates one part of the mechanism (leucine drives synthesis; HMB brakes breakdown).

Individual Variation: Who Responds Most

Age and Baseline Muscle Health

The single largest moderator of HMB response across the literature is age and baseline muscle status. Older adults with sarcopenia, in whom basal muscle protein breakdown is elevated, respond meaningfully. Healthy young resistance-trained adults, in whom breakdown is not the rate limiter, do not respond in a way meta-analysis can detect. Between those two poles, older adults without frank sarcopenia and untrained middle-aged adults tend to fall in between; the 2024 position stand notes benefits are most pronounced in untrained individuals across age.

Training Status

Untrained individuals starting a resistance program show larger relative gains from HMB than trained lifters do. This mirrors the pattern for many training-adjacent supplements: novel stimulus produces novel adaptation, and the marginal cost of assisting recovery is higher when the training itself is a novel insult. Well-trained athletes typically need longer intervention durations before an effect emerges, and the effect sizes when they do emerge are smaller.

Disuse Context

The strongest responders in the entire HMB literature are older adults during acute disuse. The Deutz 2013 bed-rest trial is the cleanest single result. Post-surgical recovery, hospitalization, and prolonged immobilization all fit the same pattern: the muscle is being asked to defend itself against elevated breakdown without the counterweight of a training stimulus, and HMB's mechanism (braking breakdown) matches the physiology.

Common Misconceptions

Misconception 1: "HMB is a legal anabolic steroid alternative."

It is not, and the marketing that frames it that way is decades old. HMB does not raise testosterone, does not stimulate androgen receptors, and does not activate the mTOR pathway in the same way leucine does. Its primary demonstrated mechanism is downregulation of the ubiquitin-proteasome protein-breakdown pathway. The Jakubowski 2020 meta-analysis in healthy young resistance-trained adults specifically found no meaningful effect on fat-free mass or 1-rep-max strength. Any framing of HMB as an anabolic alternative for a healthy trained lifter is not supported by the current best evidence.

Misconception 2: "HMB works fast."

It does not, at least not for the outcomes most people care about. The sarcopenia meta-analyses converge on 12 weeks or longer as the interval where handgrip, muscle mass, and gait speed changes reliably emerge. The bed-rest trial is the fastest-showing case, and even there the window was 10 days of immobilization with an outcome (lean mass preservation) that has to be measured before disuse ends. If you take HMB for four weeks and stop because you cannot see a difference, that is not evidence HMB does not work; that is evidence the intervention was too short.

Misconception 3: "You can get enough HMB from food."

You cannot at the doses studied. Only about 5 percent of dietary leucine gets converted to HMB. Hitting the 3 g per day dose from food alone would require roughly 500 to 600 g of protein per day, well above what almost anyone eats. The reason oral HMB supplementation was ever developed as a distinct product is precisely because the endogenous conversion is capped. If your protein intake is adequate, you are getting the small food-derived amount of HMB the diet delivers; the supplement is adding on top of that, not replacing it.

Misconception 4: "The two forms are interchangeable."

They differ pharmacokinetically. Free-acid HMB (HMB-FA) reaches peak plasma concentrations faster than calcium HMB (HMB-Ca). The 2024 ISSN position stand notes this openly. What the literature has not clearly established is whether that pharmacokinetic difference translates into a meaningful training-outcome difference. Head-to-head trials directly comparing the two forms on strength, muscle mass, or sarcopenia outcomes are thin. Practically, both forms work; if you want a pre-workout timing profile choose HMB-FA, and if you want a split-dose whole-day profile at typically lower cost choose HMB-Ca.

What the Research Suggests Going Forward

The HMB literature is in a clearer shape than it was a decade ago. The 2024 ISSN position stand, the two large 2024-2025 sarcopenia meta-analyses, the 2020 young-adult meta-analysis, and the 2013 bed-rest trial together support a fairly narrow set of claims. HMB, at 3 g per day, taken alongside resistance training, for at least 12 weeks, meaningfully improves muscle strength and function in older adults with sarcopenia. HMB, at the same 3 g per day dose, preserves lean tissue during acute disuse in older adults. HMB, at the same dose, does not meaningfully improve body composition or 1-rep-max strength in healthy young resistance-trained adults.

What is still open:

• Whether HMB is genuinely superior to leucine-rich whey protein alone at matched daily leucine, once total protein intake is adequate. The literature that separates HMB effects from adequate-protein effects is thinner than it should be.
• Whether HMB has a meaningful role in middle-aged adults (40 to 60) without frank sarcopenia. The evidence base is heavily bimodal: young trained adults and older adults with clinical sarcopenia. The middle band is underpowered.
• Whether HMB-FA is worth the price premium over HMB-Ca in real-world training outcomes. Pharmacokinetically different, functionally not clearly different in head-to-head trials.
• Whether combining HMB with vitamin D, essential amino acids, or omega-3s in the older-adult population produces additive or redundant effects. The 2024 position stand notes vitamin D status appears to matter for HMB response but does not settle whether stacking outperforms single-nutrient supplementation.
• Whether the sarcopenia benefits reported in trials of 12+ weeks extend and grow across 6 to 12 months of continuous use, or plateau early.

The takeaway for someone deciding whether to try HMB: audit yourself honestly against the two audiences the evidence separates. If you are over 60 and losing strength, or you are supporting an older adult through a bed-rest or post-surgical recovery, HMB at 3 g per day for 12+ weeks alongside a resistance program (or during the immobilization window) is a defensible, evidence-backed choice. If you are a healthy adult under 45 who lifts and eats enough protein, the honest answer is that creatine, adequate protein, and a real training program will deliver much more than HMB will. Skip it and spend the money there.

And if consistency is the actual bottleneck, no supplement fixes that. Building the habit outperforms optimizing the stack every time.

References

1. Rathmacher JA, Pitchford LM, Stout JR, et al. "International society of sports nutrition position stand: beta-hydroxy-beta-methylbutyrate (HMB)." J Int Soc Sports Nutr. 2024;22(1):2434734. doi:10.1080/15502783.2024.2434734
2. Wilson JM, Fitschen PJ, Campbell B, et al. "International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB)." J Int Soc Sports Nutr. 2013;10(1):6. doi:10.1186/1550-2783-10-6
3. Nissen S, Sharp R, Ray M, et al. "Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training." J Appl Physiol. 1996;81(5):2095-2104. PMID:8941534
4. Deutz NE, Pereira SL, Hays NP, et al. "Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults." Clin Nutr. 2013;32(5):704-712. doi:10.1016/j.clnu.2013.02.011
5. Su H, Zhou H, Gong Y, et al. "The effects of beta-hydroxy-beta-methylbutyrate or HMB-rich nutritional supplements on sarcopenia patients: a systematic review and meta-analysis." Front Med (Lausanne). 2024;11:1348212. doi:10.3389/fmed.2024.1348212
6. Li N, Chen S, He Y, et al. "Effects of oral supplementation of beta-hydroxy-beta-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis." Front Nutr. 2025;12:1522287. doi:10.3389/fnut.2025.1522287
7. Jakubowski JS, Nunes EA, Teixeira FJ, et al. "Supplementation with the Leucine Metabolite beta-hydroxy-beta-methylbutyrate (HMB) does not Improve Resistance Exercise-Induced Changes in Body Composition or Strength in Young Subjects: A Systematic Review and Meta-Analysis." Nutrients. 2020;12(5):1523. doi:10.3390/nu12051523